These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27825466)

  • 1. Current therapy guidelines for Waldenstrom's macroglobulinaemia.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):194-205. PubMed ID: 27825466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How I treat Waldenström macroglobulinemia.
    Treon SP
    Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
    Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
    Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.
    Leblond V; Kastritis E; Advani R; Ansell SM; Buske C; Castillo JJ; García-Sanz R; Gertz M; Kimby E; Kyriakou C; Merlini G; Minnema MC; Morel P; Morra E; Rummel M; Wechalekar A; Patterson CJ; Treon SP; Dimopoulos MA
    Blood; 2016 Sep; 128(10):1321-8. PubMed ID: 27432877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
    Grunenberg A; Buske C
    Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 8. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
    Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
    Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Waldenström's macroglobulinemia].
    Watanabe R
    Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Waldenström's macroglobulinemia and its individualized therapy options].
    Szemlaky Z; Mikala G
    Orv Hetil; 2017 Oct; 158(41):1604-1614. PubMed ID: 29025291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
    Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future therapeutic options for patients with Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Argyropoulos K; Palomba ML; Treon SP
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):206-215. PubMed ID: 27825467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
    Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
    Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
    Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report of consensus panel 1 from the 11
    Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
    Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
    Dimopoulos MA; Kastritis E; Owen RG; Kyle RA; Landgren O; Morra E; Leleu X; García-Sanz R; Munshi N; Anderson KC; Terpos E; Ghobrial IM; Morel P; Maloney D; Rummel M; Leblond V; Advani RH; Gertz MA; Kyriakou C; Thomas SK; Barlogie B; Gregory SA; Kimby E; Merlini G; Treon SP
    Blood; 2014 Aug; 124(9):1404-11. PubMed ID: 25027391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.